Twice-Yearly HIV Shot Called 'Closest Thing to a Vaccine'—But Who Will Get It?

A twice-yearly injection that experts are calling the 'closest thing to an HIV vaccine' is poised to reshape HIV prevention, but its potential is overshadowed by a critical question: who will actually get access? The long-acting drug, which has shown remarkable efficacy in clinical trials, requires only two doses per year, making it a pivotal factor for adherence and protection, especially in regions with high HIV incidence.

Despite its promise, the injection's high cost and limited manufacturing capacity threaten to repeat a familiar pattern in global health: wealthy nations secure supply while low- and middle-income countries wait. Previous breakthroughs, such as antiretroviral therapy and COVID-19 vaccines, saw similar inequities, with devastating consequences. Health advocates are already urging pharmaceutical companies and governments to ensure equitable distribution, warning that without deliberate action, the shot could remain out of reach for the very populations most in need.

The World Health Organization and UNAIDS have yet to announce a global allocation plan, but pressure is mounting. As the world marks another World AIDS Day, the debate over this injection underscores a broader challenge: ensuring that medical innovations benefit all, not just those who can afford them. The next steps will determine whether this breakthrough becomes a tool for ending the epidemic or another example of unequal access.